Literature DB >> 25749346

Minimal important difference of the 6-minute walk distance in lung cancer.

Catherine L Granger1, Anne E Holland2, Ian R Gordon3, Linda Denehy4.   

Abstract

The 6-minute walk distance (6MWD) is one of the most commonly used measures of functional capacity in lung cancer, however, the minimal important difference (MID) has not been established. The aims of this exploratory study are, in lung cancer, to estimate (1) the MID of the 6MWD and (2) relationship between 6MWD, demographic and disease-related factors. Fifty-six participants with stage I-IV lung cancer completed the 6MWD prior to treatment and 10 weeks later. No exercise intervention occurred. Additional measures included European Organization for Research and Treatment of Cancer questionnaire (EORTC-QLQ-C30) and questionnaires assessing function, physical activity and symptoms. MID was calculated using anchor- and distribution-based methods. The mean 6MWD decline in participants classed as deteriorated was 60 m compared with 16 m in participants classed as not-deteriorated (p = 0.01). The receiver operating curve indicated a cut-off value for clinically relevant change to be 42 m (95% confidence interval (CI) 6-75) (area under curve = 0.66, 95% CI 0.51-0.81) or a 9.5% change. Distribution-based methods indicated an MID between 22 m (95% CI 18-26) and 32 m (95% CI 20-42). Higher 6MWD correlated with better function (r = -0.42, p = 0.001), physical activity (r = 0.56, p < 0.005) and dyspnoea (r = -0.44, p = 0.001). The MID for deterioration of the 6MWD in lung cancer is estimated to be between 22 m and 42 m or a change of 9.5%.
© The Author(s) 2015.

Entities:  

Keywords:  6-minute walk distance (6MWD); Lung cancer; MID; functional capacity; minimal important difference

Mesh:

Year:  2015        PMID: 25749346     DOI: 10.1177/1479972315575715

Source DB:  PubMed          Journal:  Chron Respir Dis        ISSN: 1479-9723            Impact factor:   2.444


  26 in total

1.  Effect of an Internet-based telehealth system on functional capacity and cognition in breast cancer survivors: a secondary analysis of a randomized controlled trial.

Authors:  Noelia Galiano-Castillo; Manuel Arroyo-Morales; Mario Lozano-Lozano; Carolina Fernández-Lao; Lydia Martín-Martín; Rosario Del-Moral-Ávila; Irene Cantarero-Villanueva
Journal:  Support Care Cancer       Date:  2017-06-22       Impact factor: 3.603

2.  Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial.

Authors:  David Hui; Kelly Kilgore; Minjeong Park; Janet Williams; Diane Liu; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2016-07-09       Impact factor: 3.612

3.  Exercise capacity and cancer-specific quality of life following curative intent treatment of stage I-IIIA lung cancer.

Authors:  Duc Ha; Andrew L Ries; Peter J Mazzone; Scott M Lippman; Mark M Fuster
Journal:  Support Care Cancer       Date:  2018-02-10       Impact factor: 3.603

4.  Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer.

Authors:  Vinicius Cavalheri; Chris Burtin; Vittoria R Formico; Mika L Nonoyama; Sue Jenkins; Martijn A Spruit; Kylie Hill
Journal:  Cochrane Database Syst Rev       Date:  2019-06-17

5.  Exercise training for advanced lung cancer.

Authors:  Carolyn J Peddle-McIntyre; Favil Singh; Rajesh Thomas; Robert U Newton; Daniel A Galvão; Vinicius Cavalheri
Journal:  Cochrane Database Syst Rev       Date:  2019-02-11

6.  A pilot feasibility randomized controlled trial adding behavioral counseling to supervised physical activity in prostate cancer survivors: behavior change in prostate cancer survivors trial (BOOST).

Authors:  Linda Trinh; Arthur F Kramer; Kendrith Rowland; Dominick A Strom; Jaime N Wong; Edward McAuley
Journal:  J Behav Med       Date:  2020-09-26

7.  Effects of curative-intent lung cancer therapy on functional exercise capacity and patient-reported outcomes.

Authors:  Duc Ha; Andrew L Ries; Scott M Lippman; Mark M Fuster
Journal:  Support Care Cancer       Date:  2020-01-21       Impact factor: 3.603

8.  Persistence of the Postoperative Change in the Six-minute Walking Distance of Lung Cancer Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Ryoji Ogura; Shunsuke Iribe; Takahiko Suzuki; Haruka Kuroda; Tatsuki Sugisawa; Ikuko Okuni; Hajime Otsuka; Yoko Azuma; Akira Iyoda; Satoru Ebihara
Journal:  Prog Rehabil Med       Date:  2021-05-11

9.  Characterization of Dyspnea in Veteran Lung Cancer Survivors Following Curative-Intent Therapy.

Authors:  Duc Ha; Andrew L Ries
Journal:  J Cardiopulm Rehabil Prev       Date:  2020-03       Impact factor: 3.646

10.  A Model-Based Cost-Effectiveness Analysis of an Exercise Program for Lung Cancer Survivors After Curative-Intent Treatment.

Authors:  Duc Ha; Jacqueline Kerr; Andrew L Ries; Mark M Fuster; Scott M Lippman; James D Murphy
Journal:  Am J Phys Med Rehabil       Date:  2020-03       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.